Benjamí Oller-Salvia, PhD
Associate Professor - Junior Leader F. La Caixa - ERC Grantee
+34932672000
RESEARCH LINES
- Development of peptides for biomedical applications.
- Generation of selectively modified therapeutic proteins by genetic code expansion and bioorthogonal chemistry.
- Design of vectorised drug delivery systems, mainly targeting the brain.
- Development of stimuli-responsive proteins and nanomaterials.
COORDINATOR:
School of Engineering
Chemical & Synthetic Biology for Biotherapies
This group combines chemistry and synthetic biology to develop precision bio-nano-therapeutics based on smart proteins and to generate molecular systems that enable transport of therapeutics to the brain.
MEMBER OF:
School of Engineering
Materials Engineering
Its activities focus on three main areas: the development of new functional materials, surface engineering and biomaterials.
MANAGER:
Biotherapies Laboratory
The Biotehrapies Laboratory is specialized in the development of peptides and proteins, especially antibodies, with biomedical applications.
LATEST PROJECTS
OBGate (Creating an orthogonal gate to the brain)
Change of paradigm in the the field of brain delivery: opening a new Orthogonal Brain Gate where targeted drugs will be able to cross the blood brain barrier for the treatment of brain diseases
Funding Agency:
Research Group Link:
Materials Engineering (GEMAT)
Chemical & Synthetic Biology for Biotherapies (ChemSynBio)
APTIBody (Nanoterapias de Glioma)
Estrategia para generar anticuerpos activables y su aplicación para dirigir nanoterapias génicas a células madre de glioma
Funding Agency:
Research Group Link:
Materials Engineering (GEMAT)
Chemical & Synthetic Biology for Biotherapies (ChemSynBio)
PRO-ANTIBODY (Activación selectiva de Anticuerpos contra el Glioblastoma)
Desarrollo de anticuerpos activables para la administración de terapias génicas en las células madre de glioma
Funding Agency:
Research Group Link:
Materials Engineering (GEMAT)
Chemical & Synthetic Biology for Biotherapies (ChemSynBio)